40.85

35.67% 10.74

After Hours: 41.68 0.83 +2.03%

Viking Therapeutics Inc (VKTX)

Overview News Price History Option Chain Financials Why VKTX Down? Discussions Forecast

Viking Therapeutics Inc stock is traded at $40.85, with a volume of 40.96M. It is up +35.67% in the last 24 hours and up +20.54% over the past month. Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Previous Close:

$30.11

Open:

$37

24h Volume:

40.96M

Relative Volume:

18.51

Market Cap:

$4.77B

Revenue:

Net Income/Loss:

$-472.34M

P/E Ratio:

-9.8531

EPS:

-4.1459

Net Cash Flow:

$-340.33M

1W Performance:

+36.39%

1M Performance:

+20.54%

6M Performance:

+26.35%

1Y Performance:

+55.62%

1-Day Range:

$36.34

$41.73

1-Week Range:

$28.40

$41.73

52-Week Range:

$24.78

$43.15

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name

Viking Therapeutics Inc

Sector

Healthcare (1068)

Industry

Biotechnology (597)

Phone

858-704-4660

Address

9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA

Employee

Twitter

@viking_vktx

Next Earnings Date

2026-10-28

Latest SEC Filings

VKTX's Discussions on Twitter

Compare VKTX vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VKTX Viking Therapeutics Inc	40.85	3.73B	0	-472.34M	-340.33M	-4.1459
VRTX Vertex Pharmaceuticals Inc	514.99	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.90	80.46B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	182.56	57.48B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	963.79	61.58B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	368.08	39.20B	5.76B	514.49M	1.10B	4.4813

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Oct-29-25	Initiated	Canaccord Genuity	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Goldman	Neutral
Feb-13-25	Initiated	Scotiabank	Sector Outperform
Feb-07-25	Initiated	Citigroup	Neutral
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy
Nov-04-24	Reiterated	H.C. Wainwright	Buy
Sep-11-24	Initiated	JP Morgan	Overweight
Jun-27-24	Initiated	Morgan Stanley	Overweight
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-26-24	Reiterated	Oppenheimer	Outperform
Mar-07-24	Initiated	Jefferies	Buy
Feb-28-24	Reiterated	Oppenheimer	Outperform
May-31-23	Resumed	ROTH MKM	Buy
Mar-28-23	Reiterated	Maxim Group	Buy
Mar-17-23	Initiated	Stifel	Buy
Jul-29-21	Resumed	BTIG Research	Buy
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform
Jun-05-20	Initiated	BMO Capital Markets	Outperform
May-05-20	Initiated	Chardan Capital Markets	Buy
May-01-20	Initiated	BTIG Research	Buy
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-25-19	Initiated	Stifel	Buy
Mar-29-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-14-19	Reiterated	Maxim Group	Buy
Feb-22-19	Initiated	SVB Leerink	Mkt Perform
Dec-12-18	Initiated	B. Riley FBR	Buy
Nov-19-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-18-18	Reiterated	H.C. Wainwright	Buy
Sep-18-18	Reiterated	Maxim Group	Buy
Sep-18-18	Reiterated	Raymond James	Outperform
Jul-20-18	Initiated	SunTrust	Buy
Jun-28-18	Initiated	Raymond James	Outperform
Jun-01-18	Reiterated	Laidlaw	Buy
May-31-18	Reiterated	Maxim Group	Buy
Mar-26-18	Resumed	H.C. Wainwright	Buy
Nov-28-17	Reiterated	Maxim Group	Buy
Nov-21-17	Initiated	ROTH Capital	Buy

View All

Viking Therapeutics Inc Stock (VKTX) Latest News

Sep 13, 2026

VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3 - Stocktwits

Sep 13, 2026

Sep 12, 2026

VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits

Sep 12, 2026

VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - Stocktwits

Sep 12, 2026

Sep 11, 2026

Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits

Sep 11, 2026

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits

Sep 11, 2026

LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call - Stocktwits

Sep 11, 2026

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance

Sep 11, 2026

Sep 10, 2026

Viking Therapeutics Aims High at $92 Target, But Clinical Risks Remain - NAI500

Sep 10, 2026